Effects of acute oral Naltrexone on the subjective and physiological effects of Oral D-amphetamine and smoked cocaine in cocaine abusers

Neuropsychopharmacology

Volumn 38, Issue 12, 2013, Pages 2427-2438

  Comer, Sandra D ^a   Mogali, Shanthi ^a   Saccone, Phillip A ^b   Askalsky, Paula ^a   Martinez, Diana ^a   Walker, Ellen A ^c   Jones, Jermaine D ^a   Vosburg, Suzanne K ^a   Cooper, Ziva D ^a   Roux, Perrine ^d   Sullivan, Maria A ^a   Manubay, Jeanne M ^a   Rubin, Eric ^a   Pines, Abigail ^a   Berkower, Emily L ^a   Haney, Margaret ^a   Foltin, Richard W ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d INSERM   (France)

Author keywords

abuse liability; amphetamine; cocaine; laboratory; naltrexone

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; CAFFEINE; COCAINE; DEXAMPHETAMINE; GABAPENTIN; METHYLPHENIDATE; MODAFINIL; NALTREXONE; NICOTINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HELP SEEKING BEHAVIOR; HOSPITAL PATIENT; HUMAN; INSOMNIA; LABORATORY TEST; LOSS OF APPETITE; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SMOKING; TOBACCO; TOBACCO DEPENDENCE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADULT; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SMOKING;

EID: 84888370343     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.143     Document Type: Article

References (54)

1. Acheson A, de Wit H (2008). Buproprion improves attention but does not affect impulsive behavior in healthy young adults. Exp Clin Psychopharmacol 16: 113-123. (Pubitemid 351680704)
2. Brauer LH, Ambre J, de Wit H (1996). Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol 16: 72-76.
3. Burattini C, Burbassi S, Aicardi G, Cervo L (2008). Effects of naltrexone on cocaine-and sucrose-seeking behaviour in response to associated stimuli in rats. Int J Neurospychopharmacol 11: 103-109.
4. Carroll ME, Lac ST, Walker MJ, Kragh R, Newman T (1986). Effects of naltrexone on intravenous cocaine self-administration in rats during food satiation and deprivation. J Pharmacol Exp Ther 238: 1-7. (Pubitemid 16058286)
5. Comer SD, Haney M, Foltin RW, Fischman MW (1996). Amphetamine self-administration by humans: modulation by contingencies associated with task performance. Psychopharmacology 127: 39-46. (Pubitemid 26285681)
6. Comer SD, Lac ST, Curtis LK, Carroll ME (1993). Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats. J Pharmacol Exp Ther 267: 1470-1477. (Pubitemid 24068723)
7. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63: 210-218. (Pubitemid 43213883)
8. Corrigall WA, Coen KM (1991). Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 104: 167-170.
9. DeFulio A, Everly JJ, Leoutsakos JMS, Umbricht A, Fingerhood M, Bigelow GE et al (2012). Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend 120: 48-54.
10. Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA et al (2012). Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol 21: 74-83.
11. Epstein DH, Marrone GF, Heishman SJ, Schmittner J, Preston KL (2010). Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behav 35: 318-324.
12. Ettenberg A, Pettit HO, Bloom FE, Koob GF (1982). Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Pharmacology 78: 204-209. (Pubitemid 13250843)
13. Fillmore MT, Rush CR, Abroms BD (2005). D-amphetamineinduced enhancement of inhibitory mechanisms involved in visual search. Exp Clin Psychopharmacol 13: 200-208. (Pubitemid 41330633)
14. Fillmore MT, Rush CR, Marczinski CA (2003). Effects of d-amphetamine on behavioral control in stimulant abusers: the role of prepotent response tendencies. Drug Alcohol Depend 71: 143-152. (Pubitemid 37289024)
15. Foltin RW, Ward AS, Haney M, Hart CL, Collins ED (2003). The effects of escalating doses of smoked cocaine in humans. Drug Alcohol Depend 70: 149-157. (Pubitemid 37034167)
16. Gerrits MAFM, Kuzmin AV, van Ree JM (2005). Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone. Eur Neuropsychopharmacol 15: 297-303. (Pubitemid 40487733)
17. Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everritt BJ (2013). Attenuation of cocaine and heroin seeking by m-opioid receptor antagonism. Psychopharmacology 227: 137-147.
18. Grabowski J, Shearer J, Merrill J, Negus SS (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439-1464. (Pubitemid 39172183)
19. Guy W, Wilson WH, Brooking B, Manov G, Fjetland O (1986). Reliability and validity of SAFTEE: preliminary analyses. Psychopharmacol Bull 22: 397-401. (Pubitemid 16043811)
20. Haggkvist J, Lindholm S, Frank J (2009). The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addict Biol 14: 260-269.
21. Hersh D, Van Kirk JR, Kranzler HR (1998). Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 139: 44-52. (Pubitemid 28416881)
22. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J (2008a). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165: 1442-1448.
23. Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J (2008b). Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 33: 1856-1863. (Pubitemid 351832592)
24. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J (2004). Effects of naltrexone on the subjective response to ampthetamine in healthy volunteers. J Clin Psychopharmacol 24: 665-669. (Pubitemid 39518666)
25. Jimenez-Gomez C, Winger G, Dean RL, Deaver DR, Woods JH (2011). Naltrexone decreases d-amphetamine and ethanol selfadministration in rhesus monkeys. Behav Pharmacol 22: 87-90.
26. King AC, Meyer PJ (2000). Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66: 563-572. (Pubitemid 30440851)
27. Kosten TR, Kleber HD, Morgan C (1989). Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 44: 887-892. (Pubitemid 19085267)
28. Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M et al (1992). Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry 32: 543-548.
29. Mariani JJ, Levin FR (2012). Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am 35: 425-439.
30. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A et al (2007). Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164: 622-629. (Pubitemid 46650194)
31. McCaul ME, Svikis DS (1996). Measures of service utilization. NIDA Res Monogr 166: 225-241.
32. Mello NK, Negus SS, Lukas SE, Mendelson JH, Sholar JW, Drieze J (1995). A primate model of polydrug abuse: cocaine and heroin combinations. J Pharmacol Exp Ther 274: 1325-1337.
33. Meyer MC, Straughn AB, Man-Wai L, Schary WL, Whitney CC (1984). Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45: 15-19. (Pubitemid 14030105)
34. Oslin DW, Pettinati HM, Volpicello JR, Wolf AL, Kampman KM, O'Brien CP (1999). The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 16: 163-167. (Pubitemid 29066428)
35. Paliwal P, Hyman SM, Sinha R (2008). Craving predicts time to cocaine relapse: Further validation of the Now and Brief versions of the cocaine craving questionnaire. Drug Alcohol Depend 93: 252-259.
36. Rabkin JG, Markowitz JS (1986). Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol Bull 22: 389-396. (Pubitemid 16043810)
37. Ramsey NF, van Ree JM (1991). Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 40: 807-810.
38. Reed SC, Evans SM (2010). The effects of oral d-amphetamine on impulsivity, mood and performance in smoked cocaine users [abstract]. In College on Problems of Drug Dependence. 2010 June 12-17.
39. Scottsdale, Arizona. CPDD; 2010. p 136. Abstract nr 542.
40. Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG (2009). High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addiction 18: 356-362.
41. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J (2001). Naltrexone and relapse prevention treatment for cocainedependent patients. Addict Behav 26: 167-180. (Pubitemid 32186424)
42. Sevak RJ, Stoops WW, Glaser PEA, Hays LR, Rush CR (2010). Reinforcing effects of d-amphetamine: influence of novel ratios on a progressive-ratio schedule. Behav Pharmacol 21: 745-753.
43. Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A (2003). Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav 75: 801-808. (Pubitemid 37289465)
44. Stewart J (1984). Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacol Biochem Behav 20: 917-923. (Pubitemid 14089141)
45. Stoops WW, Glaser PEA, Fillmore MT, Rush CR (2004). Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 18: 534-543. (Pubitemid 39665121)
46. Stoops WW, Vansickel AR, Lile JA, Rush CR (2007). Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans. Pharmacol Biochem Behav 87: 20-29. (Pubitemid 46855815)
47. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2012). The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits Rockville, MD, USA.
48. Substance Abuse and Mental Health Services Administration (2012). Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings NSDUH Series H-44, HHS Publication No. (SMA) 12-4713Substance Abuse and Mental Health Services Administration, 2012: Rockville, MD, USA.
49. Todtenkopf MS, O'Neill KS, Kriksciukaite K, Turncliff RZ, Dean RL, Ostrovsky-Day I et al (2009). Route of administration affects the ability of naltrexone to reduce amphetaminepotentiated brain stimulation reward in rats. Addict Biol 14: 408-418.
50. United Nations Office on Drugs and Crime, World Drug Report (2011). United Nations Publication, Sales No. E. 10. XI. 13.
51. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
52. Wall ME, Brine DR, Perez-Reyes M (1981). Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Disposition 9: 369-375. (Pubitemid 11057598)
53. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE (1996). Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279: 524-538. (Pubitemid 27166822)
54. Winger G, Skjoldager P, Woods JH (1992). Effects of buprenorphine and other opioid agonists and antagonists on alfentaniland cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 261: 311-317.